罗莫佐单抗序贯地舒单抗治疗血液透析患者骨质疏松的疗效
这项回顾性多中心队列研究纳入34例维持性透析患者,先接受罗莫佐单抗12个月再序贯地舒单抗12个月。序贯治疗显著改善腰椎和股骨颈骨密度及骨转换标志物,但转换间隔超过4个月与TRACP-5b反弹增加相关,提示及时转换对维持骨吸收抑制至关重要。
要点
- 罗莫佐单抗序贯地舒单抗可显著改善透析患者腰椎和股骨颈骨密度及T值。
- 转换间隔超过4个月与TRACP-5b反弹增加相关,应及时转换以维持骨吸收抑制。
- 两药均可致低钙血症,需严格监测甲状旁腺激素和血钙。
核心结论
- 罗莫佐单抗序贯地舒单抗治疗与透析患者骨密度和骨转换标志物显著改善相关,及时转换对维持骨吸收抑制至关重要。
研究设计与样本
- 回顾性多中心队列研究,纳入34例维持性透析患者,接受罗莫佐单抗12个月后序贯地舒单抗12个月。
主要发现
- 序贯治疗后腰椎骨密度从0.797 g/cm²升至0.997 g/cm²,股骨颈从0.490 g/cm²升至0.537 g/cm²(p < 0.001)。
- 腰椎T值从-2.1改善至-0.9,股骨颈T值从-3.0改善至-2.7(p < 0.001)。
- 骨转换标志物水平改善,包括TRACP-5b水平显著下降。
- 转换间隔较长与TRACP-5b反弹较大相关,尤其当间隔超过4个月时。
关键数值与推荐
- 转换间隔超过4个月与TRACP-5b反弹增加相关。
临床怎么用
- 对维持性透析骨质疏松患者可考虑罗莫佐单抗序贯地舒单抗治疗,但需严格监测甲状旁腺激素和血钙以防范低钙血症。
- 应尽量缩短罗莫佐单抗至地舒单抗的转换间隔,避免超过4个月以减少骨吸收反弹。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Osteoporosis treatment in patients undergoing maintenance dialysis remains to be established. Sequential romosozumab-to-denosumab therapy improved bone mineral density and suppressed bone turnover. Shorter transition periods were associated with reduced TRACP-5b rebound, highlighting the importance of transition management and suggesting this approach as a promising option for this high-risk population. PURPOSE: Patients on dialysis have a higher risk of fractures than the general population. However, osteoporosis treatment in patients on dialysis has not been established. We aimed to evaluate the efficacy of sequential therapy with romosozumab followed by denosumab and examine the clinical impact of the transition period between these agents. METHODS: In this retrospective multicenter cohort study, 34 patients on maintenance dialysis received romosozumab for 12 months followed by denosumab for 12 months. Endpoints included lumbar spine and femoral neck bone mineral density and bone turnover marker levels. The transition period between the two agents was analyzed in relation to rebound of tartrate-resistant acid phosphatase 5b level. RESULTS: Sequential therapy improved bone mineral density (lumbar spine: 0.797-0.997 g/cm²; femoral neck: 0.490-0.537 g/cm² p < 0.001) and the corresponding T-scores (lumbar spine: -2.1 to -0.9; femoral neck: -3.0 to -2.7; p < 0.001). Bone turnover marker levels also improved, including a marked decrease in tartrate-resistant acid phosphatase 5b levels. However, as both agents may induce hypocalcemia, we implemented an internal protocol involving strict monitoring of parathyroid hormone and serum calcium levels. Consequently, some patients required a longer interval before transitioning from romosozumab to denosumab. A longer transition period was associated with greater rebound of tartrate-resistant acid phosphatase 5b level, particularly when the interval exceeded 4 months. CONCLUSION: The sequential therapy was associated with significant improvements in bone mineral density and bone turnover marker levels among patients on dialysis. Timely transition between agents appears critical to maintain suppression of bone resorption.
引用
- Kiyosumi R, Koinuma K, Nodaira Y, et al. Efficacy of sequential romosozumab-denosumab therapy in patients on hemodialysis: association with bone mineral density improvement and TRACP-5b rebound. Osteoporos Int. 2026. PMID: 42821093. doi:10.1007/s00198-026-08240-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。